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Recent studies indicate that the Notch signaling pathway
plays an important role in the development of diabetic
kidney disease and focal segmental glomerulosclerosis
(FSGS). Here we analyzed the degree of expression and
localization of Notch ligands (Jagged1 and Delta1) and
activated (cleaved) receptors (Notch1 and Notch2) in healthy
human kidneys and in renal biopsies from a wide variety of
kidney diseases. These included patients with minimal
change disease, membranous nephropathy, lupus nephritis
ISN/RPS classes III/IV/V, hypertensive nephrosclerosis,
crescentic glomerulonephritis, tubulointerstitial fibrosis, IgA
nephropathy, diabetic kidney disease, and FSGS. We found
that cleaved Notch1, Notch2, and Jagged1 are expressed on
podocytes in proteinuric nephropathies and their level of
expression correlated with the amount of proteinuria across
all disease groups. The degree of glomerulosclerosis
correlated with podocyte expression of cleaved Notch1, while
the severity of tubulointerstitial fibrosis and the estimated
glomerular filtration rate correlated with expression of
cleaved Notch1 in the tubulointerstitium. Hence, our results
raise the possibility that Notch pathway activation is a
common mechanism in the pathophysiology of a wide range
of acquired renal diseases.
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Diseases of the glomerulus, diabetic (DKD) and hypertensive
kidney disease and focal segmental glomerulosclerosis
(FSGS), are responsible for 475% of chronic kidney disease
cases in the United States.1 Genetic studies identified
mutations in a handful of genes (NPHS1, NPHS2, CD2AP,
ACN4, TRPC6, PLCE1, MYH9 and so on) responsible for
glomerulosclerosis.2 The majority of end-stage renal disease
cases, however, are not caused by a single genetic mutation.
The mechanism of glomerulosclerosis development is unclear
even when the disease mutation is identified. Recent studies
highlighted the critical role of podocytes in the development
of albuminuria and glomerulosclerosis. Interestingly, the
progression of glomerulosclerosis and chronic renal disease
on a phenotypic level seems to follow a similar pattern,
potentially indicating that a common pathway has a role in
disease progression.3,4
The Notch signaling pathway is a basic cell–cell commu-
nication mechanism. Its main components are: the ligands
Jagged (Jag1 and 2) and Delta (Dll1, 3 and 4); and the Notch
transmembrane receptor proteins (Notch1–4).5 Activation of
this signaling pathway requires cell–cell contact. Binding
of the ligand leads to a series of proteolytic cleavages of the
Notch receptor and finally to the release of the active
intracellular domain of Notch. The intracellular domain of
Notch then travels to the nucleus and binds to other trans-
criptional regulators (mainly of the CBF1/RBP-JK, SU(H),
Lag1 family) to trigger the transcription of target genes
(classically Hes and Hey genes).6
The spatially and temporally orchestrated expression of
different Notch pathway proteins has a key role in kidney
development.7–10 Notch1, Notch2, Delta1 and Jagged1
mRNA can be detected in the renal vesicle and its derivatives;
Notch2 and Jagged1 are also expressed in the collecting duct;
Notch4 expression is mainly restricted to endothelial cells,
and Notch3 to the distal portion of the S-shaped body.11,12
Both Notch1 and Notch2 are expressed in the S-shaped
body.10 Elegant studies carried out by Cheng et al.9 showed
that although both Notch1 and Notch2 expression were
detected in the early renal vesicle, genetic deletion of Notch1
did not alter kidney development, but in the absence of
Notch2 proximal kidney (glomerular and proximal tubule)
development was significantly impaired. These observations
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indicate an important subtype specificity for the two Notch
receptors.
Recent studies from our and other laboratories indicated
that activation of the Notch pathway in podocytes has a
critical functional role in the development of proteinuria and
glomerulosclerosis.13,14 Immunohistological experiments
showed that cleaved Notch1 was expressed in podocytes of
human and murine diabetic kidneys and in patients with
FSGS.13 Transgenic expression of Notch1 in podocytes caused
nephrotic syndrome and glomerulosclerosis. Genetic deletion
or pharmacological inhibition of the Notch pathway
significantly reduced albuminuria in rodent glomerular
disease models.13,15
In addition, Notch expression might not be limited to
the glomerulus and DKD, but could be observed in tubular
epithelial cells and in a variety of renal disorders as well.
Gene expression arrays performed on control and DKD
kidneys showed increased Jagged1 mRNA levels in the
tubulointerstitial compartment of DKD patients.16 Jagged1
was also identified as one of the top differentially expressed
transcripts by microarray studies carried out on murine
model of tubulointerstitial fibrosis (unilateral ureteral
obstruction).17–19
The aim of the this study was to (1) describe the degree of
expression and the localization of Notch receptors and
ligands in control and diseased human kidneys; (2) examine
whether the expression of Notch pathway molecules is
specific for DKD and FSGS, or can be observed in other
acquired renal diseases as well; (3) determine whether there
are differences in the expression of different Notch ligands
and receptors. Thus, we analyzed Notch pathway protein
expressions in control and kidney biopsy samples obtained
from 10 acquired kidney disease groups and analyzed their
correlations with renal functional and histological changes.
RESULTS
Patient characteristics
A total of 86 biopsy samples from subjects with acquired
kidney diseases were examined and grouped on the basis of
the histopathological diagnosis: minimal change disease
(n¼ 3), FSGS (n¼ 9), DKD (n¼ 9), idiopathic membranous
nephropathy (n¼ 9), lupus nephritis International Society of
Nephrology/Renal Pathology Society class III focal- or IV
diffuse-proliferative (n¼ 9), lupus nephritis International
Society of Nephrology/Renal Pathology Society class V
(membranous, n¼ 9), immunoglobulin (Ig)A nephropathy
(n¼ 8), hypertensive nephrosclerosis (n¼ 8), tubulointersti-
tial nephritis (n¼ 8), and crescentic vasculitis (n¼ 7). Seven
biopsy samples obtained from the unaffected portion of
tumor nephrectomies (n¼ 3) or from protocol living
donor biopsies (n¼ 4) were used as controls. The demo-
graphic and clinical characteristics of the research partici-
pants at the time of the kidney biopsy are summarized in
Table 1. The average age of our cohort was 43 years, with
overrepresentation of females (female¼ 59%). The highest
degree of proteinuria was observed in patients with DKD
(7.9 g/day) and with idiopathic membranous nephropathy
(7.8 g/day). Patients with crescentic glomerulonephritis
had the worst kidney function (estimated glomerular
filtration rate (GFR)¼ 26 cm3/min per 1.73m2) at the time
of the kidney biopsy.
Renal histology
Table 2 summarizes the baseline histopathological changes
observed in the kidney biopsy samples. We used the diagnosis
and the results provided by the clinical pathologist and used
during clinical patient care. We analyzed biopsy samples from
a wide range of renal disease groups, making it difficult to
compare disease-specific histological abnormalities. We
focused on the degree of glomerulosclerosis and tubulointer-
stitial fibrosis. Previous histopathological studies indicate
that the degree of glomerulosclerosis and tubulointerstitial
fibrosis correlates with renal function across the different
disease entities.20,21 Similar to previous reports, in our cohort
we found correlation between the degree of tubulointerstitial
fibrosis across all disease groups and the estimated GFR
(Supplementary Table SI). From the different disease groups,
we observed the highest degree of glomerulosclerosis (69%)
Table 1 | Demographics and clinical characteristics of the research participants
Diagnosis No. of cases Gender M/F Age (years) Hematuria Proteinuria (g/day) eGFR (ml/min)
Control 7 4/3 47±9.96 0.8±0.99 0 (0, 0.2) 92.87±11.29
DKD 9 4/5 52.5±6.7 0±0 6 (5, 10) 45.45±21.39
FSGS 9 3/6 26.8±18.5 0.2±0.41 2 (1, 2) 77.24±25.23
MCD 3 1/2 44±22.6 0.3±0.4 1.5 (0.5, 4) 75.19±17.56
IMN 9 3/5 52±19.7 0.3±0.66 7.5 (4, 9) 65.42±30.64
LN class V 9 3/5 40.5±13.8 0.6±0.66 3.5 (3, 5) 67.18±37.96
LN class III/IV 9 1/8 33±14.06 1.2±0.78 2 (1.5, 6.5) 77.17±29.23
IgAN 8 5/3 41.8±18.7 1.7±0.82 1 (0.8, 1.65) 77.23±28.97
HN 8 4/4 57.3±16 0.2±0.33 0.95 (0.65, 3.5) 40.92±25.5
TIN 8 5/3 34.6±15.9 0.6±0.99 1.25 (0.6, 2.25) 40.84±16.41
Crescentic 7 2/5 47.5±16.6 2±0.92 2 (1.5, 4) 26.52±21.18
Abbreviations: DKD, diabetic kidney disease; eGFR, estimated glomerular filtration rate; FSGS, focal segmental glomerulosclerosis; HN, hypertensive nephrosclerosis; IgAN,
immunoglobulin A nephropathy; IMN, idiopathic membranous nephropathy; LN class III/IV, lupus proliferative glomerulonephritis classes III and IV; LN class V, lupus
membranous nephropathy; MCD, minimal change disease; TIN, tubulointerstitial nephritis.
Values are expressed as means±s.d. for age, hematuria, and eGFR as median and interquartile range for proteinuria.
eGFR was calculated using the Modification of Diet in Renal Disease (MDRD) formula, hematuria is quantified as described under methods.
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and tubulointerstitial fibrosis (73%) in the DKD biopsy
samples, followed by samples obtained from tubulointerstitial
nephritis and hypertensive nephrosclerosis (Table 2). The
degree of glomerulosclerosis and tubulointerstitial fibrosis
was low in the control samples (3 and 6%, respectively).
Expression of Notch receptors and ligands in healthy adult
human kidney samples
First we characterized the expression of Notch ligands and
receptors in control ‘healthy’ human kidney samples. We
used the immunoflourescence method with established
antibodies to determine the expression of different Notch
ligands and for the receptors we used antibodies specific for
the cleaved Notch1 and Notch2.13,22–24 Podocyte-specific
expression was confirmed by double immunostaining with
podocyte marker Wilms tumor (WT)-1. We used the mouse
monoclonal WT-1 antibody that gave a cytoplasmic stain of
the human glomeruli. The quality and the specificity of the
antibodies were tested on western blots (shown in Supple-
mentary Figures S3 and S4).
Similar to previous reports, we could not observe
expression of activated Notch1, Notch2, and Delta1 in the
glomeruli of control ‘healthy’ human kidney biopsy samples
(Figure 1).13,24 Our antibody detected a faint signal for
Jagged1 in healthy glomeruli, and double immunostaining
for Jagged1 and WT-1 indicated a possible podocyte-specific
localization (Figure 1). In the tubules of healthy adult kidneys
there was no significant expression of Delta1,25 but we
occasionally observed positive immunostaining for cleaved
Notch1 and Notch2 in tubule segments (Figure 1).24
In summary, there was no significant expression of cleaved
Notch receptors in healthy adult human glomerulus, whereas
there was minimal expression of cleaved Notch1 and Notch2
in the tubulointerstitium.
Expression of Notch receptors in diseased kidney tissue
Next we analyzed the level of expression and localization of
cleaved Notch1 and Notch2 proteins in diseased kidney
samples. The amplitude of nuclear expression (examined
by 40,6-diamidino-2-phenylindole (DAPI) costaining) was
scored on a 0–4 scale (see Materials and Methods). We
validated this method by using computerized image analysis
(Image J), which showed excellent correlation (P¼ 0.01) with
the dual observer semiquantitative assessment. In addition,
this method has been used successfully recently and in the
past by other investigators.26 Representative staining images
from a single biopsy are shown in Figure 2. In addition,
images from representative scoring values are presented in
Supplementary Figure S1.
First, the presence of positive immunostaining for
activated Notch1 and Notch2 in human DKD and FSGS
samples was confirmed. Although these antibodies also show
some background staining, we only considered it as a positive
label when the nuclei were stained. In addition, we observed
positive glomerular Notch1 and Notch2 immunostaining in
multiple other renal diseases as well. Interestingly, when we
examined the pattern of expression of active Notch1 and
Notch2 across all disease groups, we found significantly
higher expression of these proteins in diseases that usually
manifest with nephrotic-range proteinuria, such as DKD,
FSGS, minimal change disease, membranous nephropathy,
lupus nephritis classes III/IV/V, or can manifest with
nephrotic-range proteinuria, such as IgA nephropathy. The
expression was not significantly different from controls in
diseases that are generally not associated with heavy
proteinuria, such as hypertensive nephrosclerosis and tubu-
lointerstitial nephritis samples (Figures 2 and 3). Delta1 was
not expressed in the glomerulus. The expression of Jagged1
on podocytes generally followed and correlated with the
expression of cleaved Notch2 (Figures 2 and 3).
Tubulointerstitial expression of cleaved Notch2 was
increased in almost all disease groups, and we could not
observe a clear disease-specific distribution (Figures 2 and 4).
Cleaved Notch1 expression in the tubulointerstitium was
significantly increased in the DKD samples (Figure 4). There
was significantly increased expression of Jagged1 and Delta1
in many different diseases, without a clear disease-specific
distribution (Figures 2 and 4).
Next, we examined whether there is a correlation between
the expression of different Notch proteins in the glomerular
Table 2 | Histopathological characteristics of the kidney biopsy samples
Disease group No. of glomeruli Glomerulosclerosis (%) Tubulointerstitial fibrosis (%)
Control 10.5 0 (0, 7) 0 (0, 10)
DKD 19.8 75 (42, 100) 80 (60, 85)
FSGS 15.4 40 (25, 55) 10 (10, 30)
MCD 8 33 (5, 100) 20 (20, 20)
IMN 15.5 16 (8.5, 23.5) 22.5 (15, 62.5)
LN class V 21 15 (0, 25) 20 (17.5, 35)
LN class III/IV 16.5 16.5 (0, 57.5) 20 (10, 32.5)
IgAN 13.8 22.5 (12.5, 54) 20 (15, 25)
HN 12.8 57.5 (29, 82.5) 35 (15, 75)
TIN 11.1 24 (0, 45) 50 (45, 65)
Crescentic 10.2 33 (0, 77) 15 (10, 50)
Abbreviations: DKD, diabetic kidney disease; FSGS, focal segmental glomerulosclerosis; HN, hypertensive nephrosclerosis; IgAN, immunoglobulin A nephropathy; IMN,
idiopathic membranous nephropathy; LN class III/IV, lupus proliferative glomerulonephritis classes III and IV; LN class V, lupus membranous nephropathy; MCD, minimal
change disease; TIN, tubulointerstitial nephritis.
Values are expressed as median (interquartile range) for glomerulosclerosis and tubulointerstitial fibrosis.
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and tubulointerstitial compartment (Supplementary Table SI).
Such analysis revealed that Notch2 expression on podocytes
correlated with Notch1 and Jagged1 expression on podocytes.
Jagged1 expression in podocytes directly correlated with
Jagged1 and Notch2 expressions in the tubulointerstitial
compartment (Supplementary Table SI). Expression of Delta1
in the tubulointerstitial compartment correlated with tubular
and podocyte expression of Notch2 and podocyte expression of
Jagged1 (Supplementary Table SI).
In summary, our results indicate that Notch ligands and
receptors are expressed in a wide range of renal diseases.
Correlation of Notch ligand and receptor expression and
renal histology
We detected an increased Notch expression in different renal
disorders without clear disease specificity; therefore, we
examined whether the expression of Notch ligands and
receptors shows correlation with histological parameters
including glomerular and tubulointerstitial fibrosis across
all disease samples. Using linear regression, we found a
positive linear correlation between podocyte and tubuloin-
terstitial expression of active Notch1 and the percent of
sclerosed glomeruli in the biopsy samples (P¼ 0.002 and
0.004, respectively) (Table 3a and Figure 5a). These results
were significant even after adjusting for the multiple
comparisons using the Bonferroni method. The expression
of active Notch1 in the tubulointerstitium showed a strong
positive linear correlation with the percent of tubulointerstitial
fibrosis, when examined across all 10 different renal disease
conditions (P¼ 0.001, b¼ 9.14) (Table 3 and Figure 5b).
In summary, these results indicate that the expression of
active Notch1 correlates with the degree of glomerular and
tubulointerstitial fibrosis virtually in all renal disease
categories.
Cleaved notch1 Merge (glom)WT-1 Merge (tubules)
Cleaved notch2
100 µm 20 µm
WT-1
Jagged1 WT-1
Delta1 WT-1
Figure 1 | Expression of Notch molecules in control human kidney. Double immunostaining of a single control (healthy) human kidney
sample with WT-1 (a–d) (fluorescein isothiocyanate; green) and cleaved Notch1 (a), and Notch2 (b), Jagged1 (c) or Delta1 (d) (Cy3; red),
nuclear stain with 4’,6-diamidino-2-phenylindole (blue) or their combination shown as indicated on the figure. glom, glomerulus.
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Renal function parameters correlate with Notch expression
Next we studied whether there is a correlation between the
expression of Notch proteins and renal functional parameters.
In our dataset, across all spectrums of acquired renal diseases,
the degree of proteinuria (analyzed as grams/day at the time of
biopsy and normalized by log transformation) correlated with
podocyte-specific expression level of active Notch1, Notch2,
and Jagged1 (Table 3c and Figure 5c). Expression of Notch
proteins in the tubulointerstitium on the other hand did not
show significant correlation with the amount of proteinuria
(Table 3c). This finding might further support the central role
of podocytes in the development of proteinuria.
Estimated GFR, at the time of biopsy, showed a statis-
tically significant association with tubulointerstitial expres-
sion of active Notch1 and Notch2, and podocyte expression
of Jagged1. Interestingly, tubular Notch1 expression and
GFR were in an inverse correlation, that is, samples with
increased Notch1 had a lower GFR, whereas tubular Notch2
expression level was in positive correlation with GFR,
as samples with increased Notch2 expression had a better
GFR (Table 3d). Our results indicate that Notch expression
across multiple renal disease groups is correlated with renal
functional parameters.
DISCUSSION
This study represents the initial step to characterize the
expression of the Notch pathway molecules in control and
diseased human kidney tissue samples. The carefully
choreographed expression of different Notch pathway
proteins has a crucial role in the kidney development.11
Our study indicates that the Notch pathway—like most
developmental pathways 27—is mostly silenced in the
Cleaved notch1 Merge (glom)WT-1 Merge (tubules)
Cleaved notch2
100 µm 40 µm
WT-1
Jagged1 WT-1
Delta1 WT-1
Figure 2 | Expression of Notch molecules in diseased human kidney biopsy sample. Double immunostaining from a single
diseased human kidney sample with WT-1 (fluorescein isothiocyanate; green) and cleaved Notch1 (a), and Notch2 (b), Jagged1 (c) or
Delta1 (d) (Cy3; red) nuclear stain with 4’,6-diamidino-2-phenylindole (blue) as indicated on the figure. The pictures were taken from a single
case of membranous nephropathy.
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glomeruli of normal mature human kidney. We found that
few tubular epithelial cells remain positive for active Notch
protein expression in the adult human kidney. Similarly, the
Kopan and coworkers using Notch1Cre-mediated mouse
genetic model also found some Notch activity in the tubular
epithelial cells of adult mice.24 It is intriguing to speculate the
role that these Notch-positive tubular cells can have in the
kidney. In other organs (best characterized in the skin and
intestinal epithelial cells), Notch-positive cells are regarded as
progenitor-like cells and are often involved in organ
regeneration, maintenance, and renewal.28,29 It would be
interesting to know whether Notch-positive cells in the
kidney have such a role.
The availability of samples from a wide variety of kidney
disorders enabled us to extend our initial observations in
DKD and FSGS.13 We found that the expression of Notch
pathway molecules is not restricted to DKD and FSGS, but
can be observed in many acquired kidney disorders without
following a disease-specific expression. Therefore, we studied
whether the expression of Notch proteins correlates with
histological and functional parameters. Using this approach,
when we analyzed samples across disease groups (regardless
of the baseline histopathological diagnosis), we found that
the expression of the cleaved Notch1 fragment in the
podocytes or glomerulus correlated with albuminuria and
glomerulosclerosis. The strength of this approach is that it
does not depend on the clinical diagnosis, which is often less
rigorous than when diagnosis is made to research studies.
Glomerular Jagged1 and Notch2 expression only showed
correlation with proteinuria. This observation makes us
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Figure 3 |Glomerular-specific expression of cleaved Notch1, 2 and Jagged1 in different renal disease groups. The relative expression
of active Notch1 (blue bar), Notch2 (red bar) and Jagged1 (yellow bar) in the glomerulus was scored in each biopsy sample. The graph
shows the mean and s.d. of the expression of each molecule. *denotes statistically significant differences (Po0.05) when compared with
controls. Cresc, crescentic; DNP, diabetic nephropathy; FSGS, focal segmental glomerulosclerosis; HN, hypertensive nephrosclerosis;
IgAN, immunoglobulin A nephropathy; IMN, idiopathic membranous nephropathy; LN, lupus nephritis; MCD, minimal change disease.
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Figure 4 | Tubulointerstitial expression of cleaved Notch1, 2, Jagged1 and Delta1 in different renal disease groups. The relative
expression of active Notch1 (blue bar), Notch2 (red bar), Jagged1 (yellow bar) and Delta1 (light blue bar) in the tubulointerstitium was
scored in each biopsy sample. The graph shows the mean and s.d. of the expression of each molecule. *denotes statistically significant
differences (Po0.05) when compared with controls. Cresc, crescentic; FSGS, focal segmental glomerulosclerosis; HN, hypertensive
nephrosclerosis; IgAN, immunoglobulin A nephropathy; IMN, idiopathic membranous nephropathy; LN, lupus nephritis; MCD, minimal
change disease.
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speculate that podocyte Notch expression might represent a
final common (downstream) pathway for albuminuria and
glomerulosclerosis development. To our knowledge, this is
one of the first molecules whose expression shows correlation
with renal function across multiple human disease samples.
We also studied the relationship between Notch expres-
sion and renal function parameters. Most previous immuno-
histological studies examined the expression of several
other molecules (podocyte nephrin, podocin, CD2AP,
a-actinin, WT-1, tubular kidney injury molecule-1, tissue
transglutaminase-2) and their associations with morpho-
logical damage and baseline clinical data, but not with renal
function.30,31 A very nicely performed study by Eardley
et al.32 showed correlation between albuminuria and mono-
cyte chemoattractant protein-1 expression in the kidney. Our
functional analysis across multiple disease groups revealed
some interesting observations. We found that while podocyte
expression of Notch molecules showed the best correlation
with albuminuria, Notch1 expression in the tubules showed
the strongest association with estimated GFR and with
tubulointerstitial fibrosis. These observations are consistent
with some previous pathological and clinical studies indicat-
ing that the degree of tubulointerstitial fibrosis shows the
strongest correlation with renal function.20,21 On the basis of
our results, we can further hypothesize that the Notch
pathway can also have a role in the development of tubulo-
interstitial fibrosis. Previous studies indicated the expression
of Notch1/Jagged1 in a mouse model of tubulointerstitial
fibrosis17 and their role in the transforming growth factor-b-
induced epithelial-to-mesenchymal transformation in vitro.18
It is also worth mentioning that we could not detect a clear
correlation between podocyte expression of Notch molecules
and renal function or the degree of tubulointerstitial fibrosis at
the time of biopsy. These results make us speculate on the
differential role for the Notch pathway in podocytes and in
albuminuria development and the expression of Notch in
tubular cells and in tubulointerstitial fibrosis development.
In our study we found differences in expression of
different ligands and receptors. Most importantly, increased
Notch1 levels were associated with increased tubulointer-
stitial fibrosis and decreased estimated GFR, whereas
tubulointerstitial expression of Notch2 was observed in
samples with less tubulointerstitial fibrosis and better renal
function. These results would suggest that similar to renal
Table 3 | Result of the linear regression analysis of Notch
expression and histological and functional renal parameters
B co-efficient 95% CI P-value
(a) Proteinuria (log)
Podocyte ICN1 (n=79) 0.17 0.004, 0.35 0.056
Podocyte ICN2 (n=90) 0.22 0.007, 0.43 0.04
Podocyte Jag1 (n=71) 0.33 0.05, 0.61 0.02
Tubular ICN1 (n=72) 0.21 0.01, 0.43 0.07
Tubular ICN2 (n=72) 0.03 0.27, 0.21 0.80
Tubular Jag1 (n=75) 0.10 0.44, 0.23 0.54
Tubular Delta1 (n=80) 0.13 0.07, 0.32 0.22
(b) eGFR
Podocyte ICN1 (n=85) 1.24 4.29, 6.78 0.66
Podocyte ICN2 (n=86) 1.68 8.42, 5.07 0.62
Podocyte Jag1 (n=75) 8.66 0.29, 17.0 0.04
Tubular ICN1 (n=78) 12.2 18.4, 5.93 o0.001
Tubular ICN2 (n=84) 10.57 3.36, 17.8 0.005
Tubular Jag1 (n=75) 7.59 2.25, 17.4 0.13
Tubular Delta1 (n=80) 1.16 4.86, 7.19 0.70
(c) Glomerulosclerosis
Podocyte ICN1 (n=83) 8.68 3.31, 14.0 0.002
Podocyte ICN2 (n=83) 2.22 4.78, 9.23 0.53
Podocyte Jag1 (n=75) 6.9 15.7, 1.89 0.12
Tubular ICN1 (n=83) 9.87 3.20, 16.5 0.004
Tubular ICN2 (n=83) 4.02 11.8, 3.74 0.31
Tubular Jag1 (n=75) 4.95 15.3, 5.37 0.34
Tubular Delta1 (n=79) 1.71 4.37, 7.79 0.58
(d) Tubulointerstitial fibrosis
Podocyte ICN1 (n=83) 4.94 0.32, 9.56 0.04
Podocyte ICN2 (n=83) 4.02 1.75, 9.80 0.17
Podocyte Jag1 (n=80) 1.83 9.28, 5.62 0.63
Tubular ICN1 (n=78) 9.14 3.63, 14.7 0.001
Tubular ICN2 (n=78) 4.50 10.9, 1.92 0.17
Tubular Jag1 (n=75) 1.38 10.0, 7.29 0.75
Tubular Delta1 (n=79) 0.36 5.48, 4.77 0.89
Abbreviation: ICN, Notch intracellular domain.
Results of linear regression analysis (significance and correlation coefficient) of
Notch pathway protein expression (podocyte and tubulointerstitial active Notch1,
Notch2, Jagged1 and Delta1) and proteinuria (log transformed) (a), estimated GFR
(b), glomerulosclerosis (log transformed) (c), tubulointerstitial fibrosis (d). The
Bonferroni adjusted P-value 0.002 or the unadjusted P-value 0.05 for this analysis
were considered statistically significant.
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Figure 5 |Correlation plots of podocyte Notch1 expression
and glomerulosclerosis and tubulointerstitial fibrosis and
tubulointerstitial expression of active Notch1. Scatter plot with
fitted values (red line) and 95% confidence (green line) intervals
for (a) percent glomerulosclerosis and podocyte expression of
Notch1 and (b) and tubular expression of Notch1 and
tubulointerstitial fibrosis.
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development, in which Notch1 and Notch2 have a non-
redundant role in kidney development, Notch1 and Notch2
might have different roles in tubulointestitial fibrogenesis as
well.7 A single study that looked at the function of Notch2
proteins in experimental acute kidney injury showed that
tubular Delta1 and Notch2 expression is increased during
ischemic injury in vivo. In vitro coculturing experiments also
showed that Delta1 stimulated proliferation of cultured
tubular epithelial cells, suggesting that Delta1 may have a role
in the tubular regenerative process.25 What balances the
differential expression of these molecules is unknown at the
present time, but one could speculate that growth factors (for
example, VEGF and transforming growth factor-b) could be
important. Although our study is observational in nature,
nevertheless might support the concept of previous experi-
ments indicating the different roles for the various Notch
isoforms.
We used fluorescent immunohistochemistry-based analy-
sis of renal biopsy samples to detect Notch receptors and
ligands. The approach has several advantages, most impor-
tantly that it can detect the active signaling unit of Notch1
and Notch2 proteins, as opposed to in situ hybridization that
can only detect transcript levels. It is well recognized that
transcript levels might not directly correlate with cleaved
protein expression. These cleavage site-specific antibodies
have been used on multiple occasions previously and seem to
be highly specific.13,24 In addition, the immunohistochem-
istry approach can be carried out on small amounts of frozen
or paraffin-embedded tissues. Potential limitations of our
study are that it is from a single center and analyzed different
disease groups together. For example, we only had a limited
number (n¼ 3) of biopsies with minimal change disease, as it
is not very common in adults. Another limitation of the
study is that the results have not been adjusted for multiple
comparisons and therefore, they should be interpreted
carefully, and need to be confirmed in larger studies with
greater statistical power. It is not clear whether such adjust-
ment should be made because this is the first and exploratory
analysis defining the expression of the Notch pathway in
human kidney biopsy samples and second because some of
the most recent results suggest that the Bonferroni correction
might be too stringent for multiple comparisons.33 However,
even in case we use the very stringent P-values suggested
by the Bonferroni adjustment, the association between
glomerulosclerosis and podocyte Notch1 expression remains
statistically significant. Similarly, the association between
tubule expression of Notch1 and tubulointerstitial fibrosis
and glomerular filtration rate remained statistically signi-
ficant, further supporting our findings.
In conclusion, we found that in the human kidney Notch
ligands and receptors are expressed in a wide range of renal
diseases, with podocyte-specific Notch expression showing
correlation with albuminuria and glomerulosclerosis. Tubu-
lointerstitial abundance of specific Notch-signaling molecules
showed association with renal function and histologic
predictors of renal outcome. Our findings could indicate
that Notch activation might represent a common down-
stream pathway for albuminuria, glomerulosclerosis, and
tubulointerstitial fibrosis. These results may help to under-
stand the development of chronic renal disease and generate
novel candidate molecular markers and therapeutic targets.
MATERIALS AND METHODS
Research subjects
Renal biopsy samples diagnosed at the Montefiore Medical Center
from 2004 to 2007 were reviewed and cases with sufficient material
(at least five glomeruli) were selected for further study. Renal biopsy
samples were processed by standard techniques for light, immuno-
fluorescent and electron microscopy and clinical diagnosis was made
on the basis of these stainings. Corresponding histopathological and
clinical information was collected by chart review. The percent
glomerulosclerosis and tubulointerstitial fibrosis was obtained from
the standard pathology report and represent the percentage of
glomeruli or tubulointerstitium with fibrosis. The degree of
hematuria was assessed based on the result of urinalysis obtained
within 2 weeks prior to the biopsy. The following scale was used: 0 if
o5 RBCs per high-power field (HPF), 1 if 6–20 RBCs/HPF, 2 if
21–50 RBCs/HPF, and 3 if451 RBCs/HPF. The study was approved
by the Institutional Review Board.
Immunostaining
Tissue-Tek (OCT)-embedded frozen kidney tissue was cryotome cut
at 5 mm. Kidney sections were fixed in ice-cold acetone for 10min,
then washed with phosphate-buffered saline for 5min. The tissue
was blocked with 1% fish skin gelatin for 30min at room
temperature. Primary antibodies diluted in 1% fish skin gelatin
(anti-Notch1 1:200, anti-Notch2 1:200, anti-Jagged 1:200, anti-
Delta1 1:100, anti-WT-1 1:100) were incubated at 41C overnight.
Thereafter, slides were washed in phosphate-buffered saline and
secondary antibodies (goat anti-rabbit Cy3 1:500, donkey anti-
mouse fluorescein isothiocyanate 1:150) were incubated for 30min
at room temperature. Slides were then washed with phosphate-
buffered saline, counterstained with 4’,6-diamidino-2-phenylindole,
and mounted with Fluoromount. The following primary antibodies
were used: cleaved Notch1 (Abcam, ab8925, Cambridge, MA) rabbit
polyclonal IgG, cleaved Notch2 (Abcam, ab8926) rabbit polyclonal
IgG, Jagged1 (Santa Cruz, sc-8303, Santa Cruz, CA) rabbit
polyclonal IgG, Delta1 (Santa Cruz, sc-9102) rabbit polyclonal
IgG, WT-1 (Santa Cruz, sc-81617) mouse monoclonal IgG,
specificity of the primary antibodies used in this study was tested
on western blots (Supplementary Figure S3). Control staining with
secondary antibodies was only performed to evaluate whether there
was presence of nonspecific background antibody binding (pictures
shown in Supplementary Figure S2).
Image analysis
Slides were examined with Nikon (Melville, NY) Eclipse TE300
fluorescence microscope and pictures were taken with SPOT
Diagnostic (Sterling Heights, MI) CCD camera. Immunostaining
was evaluated in a blinded manner. A 0–4 relative scale was used to
grade the amount of immunostaining: 0,o5% staining; 1þ , 5–10%
staining; 2þ , 10–25% immunostaining; 3þ , 25–50% immuno-
staining; 4þ , 450% immunostaining. In case of linear staining,
such as Jagged1, the percentage of positive staining in relation to the
total glomerular cross-sectional area defines the scale. In case of
discrete nuclear staining of cleaved Notch1 and Notch2, the
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percentage of positively stained nuclei per all glomerular nuclei
has been used. Coimmunostaining for podocyte marker WT-1 and
4’,6-diamidino-2-phenylindole and the use of overlapping micro-
scope image aided in determination of glomerular podocyte or
tubulointerstitial localization of Notch-complex proteins. Slides
were analyzed by two independent observers blinded to the
diagnosis. There was a very good congruence observed in the dual
blinded scoring (Pearson’s correlation 0.97). For each stained
molecule and each case, average glomerular and tubulointerstitial
immunofluorescence intensity and amount were determined.
Statistical analysis
Results are presented as the mean and standard deviation, or median
and interquartile range when necessary for our descriptive statistical
data. Continuous variables were assessed by analysis of variance
followed by Tukey test. Nonparametric data were assessed by
Kruskal–Wallis test followed by Dunn’s test. Pearson’s correlations
were used to evaluate the association between two continuous
variables. The nonlinearly distributed outcome variable for protein-
uria was logarithmically transformed. Owing to the hypothesis-
generating exploratory analysis of these data, there is some
argument in the medical literature about whether or not correction
needs to be made for multiple comparisons.33 The Bonferroni
adjusted P-value for this analysis is 0.002.
Linear regression was carried out to evaluate associations
between stained molecules and baseline parameters. A two-sided
P-valueo0.05 indicated statistical significance. Error bars represent
standard deviation. All statistical analyses were carried out using
STATA 10.0 (College Station, TX, USA).
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